Skip to content

First Report of a New Exoskeleton in Incomplete Spinal Cord Injury

First Report of a New Exoskeleton in Incomplete Spinal Cord Injury: FreeGait®

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06137456
Enrollment
14
Registered
2023-11-18
Start date
2022-01-01
Completion date
2023-11-01
Last updated
2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injuries, Walking, Difficulty

Brief summary

The goal of this clinical trial is to compare the effects of exoskeletal robotic therapy and conventional exercise therapy in incomplete spinal cord injury (SCI). The main questions it aims to answer are: * Is exoskeletal robotic therapy effective in improving functional ambulation in SCI? * Is exoskeletal robotic therapy effective in enhancing Activities of Daily Living in SCI? Participants treated with either: * Exoskeletal robotic therapy along with conventional exercise therapy, or * Only conventional exercise therapy.

Detailed description

Background: Intensive walking practice is a task that requires performance above the limits of conventional therapy. As a solution, robot-assisted exoskeletons that allow walking on the ground are produced. The exoskeletons can allow the user to perform intense, targeted, and multi-repetitive movements and at the same time provide stability and balance during walking. In this study, a new robot-supported exoskeleton system was used for gait and balance rehabilitation. This study is important as the first clinical study of a new walking system. The primary aim of the study was to evaluate the effect of the FreeGait® exoskeleton system (BAMA Technology, Ankara, Türkiye) on gait parameters in patients with motor incomplete spinal cord injury. The secondary aim was to assess its impact on quality of life and independence. Methods: Fourteen participants with incomplete spinal cord injury were included in the study. An average of 20.7 sessions of exoskeleton therapy was administered to the study group. Gait training was attempted to be diversified as much as possible during the exoskeleton training. 10MWT, Timed Up and Go Test (TUG), WISCI II, Berg Balance Scale (BBS), Visual Analogue Scale (VAS) for fear of falling, Spinal Cord Independence Measure (SCIM III), World Health Organization Quality of Life Scale-Short Form (WHOQOL - BREF) were used for evaluation. Results: WISCI II levels improved significantly in the study group (p = 0.031). Overground walking speed means calculated from 10MWT increased by 66%, twofold compared to the control group (p = 0.016, p = 0.063, respectively). The mobility subscale of SCIM III, the total SCIM III scores, and the WHOQOL-BREF physical health domain score increased significantly, contrary to the control group (p \< 0.05). However, there was no difference in the mean change of all measurements between groups (p \> 0.05). Conclusions: Gait training with the new exoskeleton system contributes to functional walking skills. It is possible that the residual motor learning ability, together with the balance and compensation mechanisms, played a role in the outcome. It is also important that this improvement in functional mobility is reflected in ADLs. It can be supposed that walking in different patterns, and speeds gives a way to simulate daily living conditions, which is the basis of the achievements in this study.

Interventions

DEVICEExoskeletal robotic therapy for walking.

Exoskeletal robotic therapy for walking. Therapy sessions were scheduled for 40 minutes each. The study group performed exoskeleton walking and balance exercises 3 days a week.

Conventional treatment consisted of walking and balance exercises, stretching, strengthening, and mobility exercises, for 40 minutes, 5 days a week.

Sponsors

Ankara City Hospital Bilkent
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* SCI below T4, * Patients with AIS (American Spinal Injury Association Impairment Scale) C or D injury, * Bilateral quadriceps femoris manual test scores ≥ 2, * Upper extremity manual muscle test scores = 5, * Participants with adequate spinal stabilization

Exclusion criteria

* Severe spasticity (Modified Ashworth Scale ≥ 3), * Difference in leg length, * Pregnancy, osteoporosis, * Contracture, or limited range of motion

Design outcomes

Primary

MeasureTime frameDescription
Walking Index in Spinal Cord Injury II23 monthsWalking Index in Spinal Cord Injury II for walking independence level assessment

Secondary

MeasureTime frameDescription
Timed Up and Go Test23 monthsTimed Up and Go Test overground walking assessment
Berg Balance Scale23 monthsBerg Balance Scale for balance assessment
Ten-Meter Walking Test23 monthsTen-Meter Walking Test for overground walking speed assessment
Spinal Cord Independence Measure (SCIM III)23 monthsSpinal Cord Independence Measure (SCIM III) for activity of daily living assessment
World Health Organization Quality of Life Scale-Short Form (WHOQOL - BREF)23 monthsWorld Health Organization Quality of Life Scale-Short Form (WHOQOL - BREF) for quality of life assessment
Visual Analogue Scale23 monthsVisual Analogue Scale (VAS) for fear of falling assessment

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026